The standard of care for diagnosing coronary artery disease (CAD) has changed. CCTA paired with AI-powered Plaque Analysis has emerged as a tool of choice to identify, risk stratify and stage CAD, and notably, manage and treat patients in a far more informed way. Join us to hear from three key opinion leaders as they present data and new case studies demonstrating how Plaque Analysis can help with diagnosis and management of patients with suspected CAD. One physician even shares how he has benefitted from CCTA + Plaque Analysis. It’s a great story.

Diagnosing female patients with coronary artery disease (CAD) has many challenges. Join us to hear from three key opinion leaders as they present data and new case studies demonstrating these difficulties, and the guidelines and pathways that help with diagnosis and management of women with suspected CAD.

If you’re looking to grow your CCTA program or start one, listen in. Learn from cardiology and radiology experts at Wellstar Health System who have built a successful CCTA program.

What are the benefits of accurately assessing plaque burden in your patients with suspected coronary artery disease (CAD)? Listen to two cardiologists discuss the advantages of using a coronary CTA pathway along with AI-based plaque analysis and physiology to understand a patient’s risks of cardiovascular events.

Lesion-specific physiology matters! Three leading experts review cases that demonstrate why and how lesion-specific physiology can inform treatment for patients with CAD and lessons learned from 10 years of FFR_CT interpretation.

We need to change the conversation on women, chest pain and coronary artery disease (CAD). Two leading experts will review women’s unique biology, risk factors, and presenting symptoms of heart disease during this webinar. They also will discuss better ways to detect and diagnose CAD, and how cardiac CT and FFR_CT can identify those at-risk and in need of treatment. Join us to learn how cardiovascular (CV) teams can identify women at risk of CAD who are most likely to benefit from further testing and treatment.

For over two decades, the World Heart Federation has been leading the World Heart Day movement—informing people around the world that cardiovascular disease (CVD), including heart disease and stroke, is the leading cause of death globally

Michael Morris, MD, director of Cardiac MR and Cardiac CT at Banner Health and Wesley O'Neal, MD, director of cardiac CT and nuclear cardiology at Cone Health, discuss the results of SMART-CT Study.